Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)

NCT01334918 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01334918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01334918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
April 26, 2011
Completion date
July 2, 2012
Enrollment
124 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease (cad)